“A new study has found that CBD, one of the main compounds in cannabis, shows significant antiviral properties, and specifically when it comes to protecting the body from the Hepatitis C virus (HCV).
The study, conducted by Dr. Lowe, a Professor from the University of Maryland School of Medicine, which was published in the highly-respected Pharmacognosy Research Journal, suggests that CBD could be an effective treatment for more than 3 million Americans who suffer from HCV.
While there is already a cure on the market for Hepatitis C, it costs in excess of $100,000 for a 12-week course. This treatment is effective, and few side effects have been reported. The main issue being that not a lot of people can afford the overly heavy price tag, even if it could be a life saver for them.
In 2017, it is estimated that at least 20,000 Americans will die from liver cancer, most of which due to HCV. Researchers who carried out the study, found that the phytochemical, CBD, inhibits HCV, as well as being generally antiviral.”
The authors note the research is preliminary but very much warrants thorough followup. Much more in the article.
In a world where our state medical association (which apparently does little reading of the studies we keep finding with ease) keeps doggedly asserting that “plants aren’t medicine” and that the potential of medical cannabis remains unknown, even we keep getting floored by the sheer breadth of possible MC applications that bode to actually change the course of mainstream medicine overall.
The release of the Utah Patients Coalition Initiative for signature gathering can’t come soon enough for the best interest of patients from all we’ve learned from the research literature over the last four years…..
#MMJ #Research #Hepatitis #UTpol #Initiative18 #TRUCE
See full article – Groundbreaking Study Finds CBD Inhibits Hepatitis Virus – CannaTech News